RS 5614
Alternative Names: RS-5614; TM-5614Latest Information Update: 29 Mar 2024
At a glance
- Originator Renascience
- Developer Akita University; Hiroshima University; Renascience; Tohoku University; Tokai University
- Class Antineoplastics; Small molecules
- Mechanism of Action Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic myeloid leukaemia
- Phase II COVID 2019 infections; Haemangiosarcoma; Interstitial lung diseases; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 20 Feb 2024 Phase-II clinical trials in Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Japan (PO), prior to February 2024
- 20 Feb 2024 Phase-II clinical trials in COVID-2019 infections in USA, Turkey (PO), prior to February 2024 (Renascience pipeline, February 2024)
- 20 Feb 2024 Phase-II clinical trials in Haemangiosarcoma (Combination therapy, Second-line therapy or greater) in Japan (PO), prior to February 2024